Abstract

Invasive fungal disease (IFD) in hematopoietic stem cell transplantation is associated with high morbidity and mortality. As the antifungal host response determines risk and outcome of IFD, there is growing interest in adoptive immunotherapy using T cells or natural killer (NK) cells. Although the NK-92 cell line has been tested as anticancer therapy in clinical trials, data on the antifungal activity of NK-92 cells are lacking. Here, we show that the NK-92 cell line exhibits considerable fungal damage on all medically important fungi tested, such as different species of Aspergillus, Candida, mucormycetes, and Fusarium. The extent of fungal damage differs across various species of mucormycetes and Fusarium, whereas it is comparable across different species of Aspergillus and Candida. Interferon (IFN)-γ levels in the supernatant were lower when NK-92 cells are co-incubated with Aspergillus fumigatus, Candida albicans, or Rhizopus arrhizus compared to the levels when NK-92 cells are incubated alone. Different to primary human NK cells, no increase of perforin levels in the supernatant was observed when the fungi were added to NK-92 cells. Our in vitro data demonstrated that the NK-92 cell line could be a feasible tool for antifungal immunotherapy, but data of animal models are warranted prior to clinical trials.

Highlights

  • Pediatric and adult patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT) are at an increased risk for invasive fungal disease (IFD), which is still associated with high morbidity and mortality [1,2]

  • The antifungal activity of natural killer (NK)-92 cells was tested with different species of Aspergillus (n = 4), Candida (n = 3), mucormycetes (n = 6), and Fusarium (n = 4)

  • Our data show that NK-92 cells damaged all Aspergillus spp. tested, namely, A

Read more

Summary

Introduction

Pediatric and adult patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT) are at an increased risk for invasive fungal disease (IFD), which is still associated with high morbidity and mortality [1,2]. Despite the availability of new and potent antifungal compounds, such as broad-spectrum triazoles or echinocandins, the mortality of invasive fungal infections remains unacceptably high, and studies report on mortality rates between 50% and over 80% [3,5]. Aspergillus spp., Candida spp., as well as mucormycetes are the most important pathogens causing these infections, which may occur despite potent antifungal prophylaxis [1,2].

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call